Kimberly Muller

Kimberly Muller is the Executive Director of CU Innovations where she leads innovation for the University of Colorado Anschutz Medical Campus. Kimberly’s business development responsibilities include investing, company creation, innovation management, forming key strategic industry partnerships, and licensing. Large-scale industry collaborations have been established in areas such as AI and drug development.  She also manages several investment funds, including a $10 million innovation grant fund, a $50 million early-stage venture fund, a $75 million follow-on fund, and partners with UCHealth on a $200 million growth stage fund.

Kimberly joined the University of Colorado from Yale University where she was formerly the Deputy Director of the Yale Entrepreneurial Institute (YEI), and managed New Ventures in the Office of Cooperative Research. During Kimberly’s tenure, Yale’s Office of Cooperative Research started more than 70 new ventures that have raised over $5 billion in investor capital.

Previously, Kimberly started and sold companies in the biotech, tech, and clean energy fields, companies included Curagen Corporation (acquired by Celldex Therapeutics), 454 Life Science (acquired by Roche), and Arbor Fuel, a biofuel company that utilized recombinant microorganisms for the production of ethanol and butanol. Kimberly began her career in New York as a patent attorney for Chadbourne and Parke, LLP.

Kimberly has a graduate degree in Genetics and received her law degree with highest honors from the University of Connecticut School of Law.